No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Genmab A/S, established in 1999 and headquartered in Copenhagen, Denmark, is a biotechnology firm specializing in the development of antibody therapeutics for cancer and various other medical conditions, primarily operating from its Danish base. The company currently offers several key therapies to the market, including DARZALEX, a human monoclonal antibody targeting multiple myeloma (MM); teprotumumab for thyroid eye disease; and Amivantamab, indicated for advanced or metastatic gastric/esophageal cancer and non-small cell lung cancer (NSCLC). Genmab's extensive product pipeline features daratumumab for MM, non-MM blood cancers, and AL amyloidosis, alongside GEN1047. Other developing treatments include tisotumab vedotin for cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for hematological malignancies. Furthermore, the company is advancing Inclacumab (currently in Phase 3 for vaso-occlusive crises), Camidanlumab tesirine (for Hodgkin lymphoma and solid tumors), JNJ-64007957 and JNJ-64407564 (for MM), PRV-015 (for celiac disease), Mim8 (for hemophilia A), and Lu AF82422 (for multiple system atrophy). Beyond these, numerous pre-clinical programs are actively underway. Genmab engages in significant strategic partnerships, including a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. It also collaborates with argenx on novel therapeutic antibody discovery and commercialization in immunology and oncology, with AbbVie for epcoritamab's development, and maintains alliances with BioNTech, Janssen, and Novo Nordisk A/S.
www.genmab.comNo one on the platform currently holds GE9.F.
No tracked institution reports a position in GE9.F as of their last filing.
No one on the platform has traded GE9.F yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.7% | 19.9% | 22.9% | — | — | — |
| Rev. Growth % | -82.1% | -17.6% | ||||
| Profit Margin % | 25.9% | 32.2% | 40.9% | |||
| Free Cash Flow Margin % | 30.9% | 31.3% | 33.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.4B | +18.9% | $11.63 | $10.60–$12.52 | — | 1 |
| 2027 | $5.2B | +17.7% | $17.16 | $15.65–$18.47 | — | 1 |
| 2028 | $6.2B | +19.8% | $25.81 | $23.54–$27.78 | — | 1 |
| 2029 | $6.4B | +2.9% | $25.66 | $23.40–$27.62 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $3.12 | $4.30 | +37.8% |
| 2026-05-07 | $1.35 | $0.72 | -46.8% |
| 2026-02-17 | $2.39 | $0.43 | -82.2% |
| 2025-11-06 | $4.14 | $5.52 | +33.3% |
| 2025-06-30 | $3.39 | $4.60 | +35.7% |
| 2025-03-31 | $2.17 | $2.78 | +28.1% |
| 2024-12-31 | $3.61 | $8.06 | +123.3% |
| 2024-09-30 | $2.77 |
| $2.66 |
| -4.0% |
| $10.6B |
| — |
| IDP.DEBiogen Inc. | $165.68 | +2.56% | $24.5B | — |
| ILU.DEIllumina, Inc. | $124.28 | +0.60% | $18.8B | — |
Source: Financial Modeling Prep · peers by sector/industry